Clinical Trial Update: Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial evaluating capecitabine for metastatic non-clear cell renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Capecitabine (Xeloda) (Capecitabine)

Snippet

Sponsor: Kidney Cancer Research Bureau | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: COMPLETED